This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Polycythaemia vera진성적혈구증가증

Contents and key points
ItemDetails
A. Classification codesICD-10: D45 (Polycythaemia vera) | Special Copayment Reduction: V193 (Special copayment reduction for cancer: 5% copayment for 5 years from the registration date)
B. SynonymsOsler-Vaquez disease, primary polycythemia, JAK2-mutated myeloproliferative neoplasm, polycythaemia rubra vera, PV, PRV
C. Adult onsetMostly first diagnosed in the 60s but can present after age 40. Early diagnosis is important because of the high thrombotic risk; slightly more common in men.
1. HistoryFirst described by Vaquez in 1892 and named Osler-Vaquez disease after further characterization by Osler in 1903; the discovery of the JAK2 V617F mutation in 2005 revolutionized understanding of its pathogenesis.
2. CausesThe JAK2 V617F somatic mutation is the cause in about 97%; JAK2 exon 12 mutations are found in the remainder. Genetic predisposition and environmental factors act in combination.
3. GeneticsThe JAK2 V617F gain-of-function mutation causes EPO-independent proliferation of the erythroid lineage, accompanied by mutations in epigenetic regulator genes such as TET2 and DNMT3A.
4. General epidemiologyAnnual incidence about 1–2.8 per 100,000; median age at diagnosis about 60–65 years; male predominance; lower incidence in Asians than in Westerners.
5. PathophysiologyHyperactivation of JAK-STAT5 signaling by JAK2 V617F causes EPO-independent erythroid proliferation, and thrombotic, hemorrhagic, and fibrotic complications develop sequentially.
6. SymptomsAquagenic pruritus (after bathing), headache, dizziness, tinnitus, symptoms of erythrocytosis, microvascular symptoms (burning hands and feet, erythromelalgia), and fatigue are the main symptoms.
7. SignsFacial plethora, splenomegaly (about 70%), hepatomegaly, conjunctival injection, hypertension, and signs related to prior thrombosis are found.
8. ScreeningOften discovered incidentally by elevated hemoglobin/hematocrit; in familial cases, JAK2 testing of relatives; regular blood counts are important for early detection.
9. DiagnosisWHO 2022 criteria: diagnosed when all 3 major criteria—elevated Hb + JAK2 mutation + bone marrow biopsy (trilineage proliferation, pleomorphic megakaryocytes)—or 2 major + 1 minor criterion are met.
10. TreatmentPhlebotomy (target hematocrit < 45%) + low-dose aspirin is the basic treatment for all patients; hydroxyurea or interferon alfa is used in the high-risk group.
11. PrognosisMedian survival about 11.9 years; 5-year survival rate about 88%; the main causes of death are thromboembolism, bleeding, secondary myelofibrosis, and transformation to acute leukemia.
12. PreventionMinimizing thrombotic risk (smoking cessation, weight management, control of cardiovascular risk factors), maintaining regular phlebotomy, and improving adherence to drug therapy are key to preventing complications.
13. ReferencesPolycythemia vera: 2024 update on diagnosis, risk-stratification, and management … and 9 other papers

1. History

Polycythemia vera (PV) was first described in 1892 by the French physician Louis Henri Vaquez, who described it as a cyanotic heart disease accompanied by hepatosplenomegaly and excessive erythrocyte proliferation. Vaquez argued that this disease was an independent entity distinct from simple secondary erythrocytosis. Later, in 1903, the eminent Canadian-born internist William Osler systematically described 4 additional cases and summarized the clinical features, and the disease was named "Osler-Vaquez disease" and recorded in history.

In the early 20th century, radioactive phosphorus (32P) therapy was introduced into PV management and used to suppress blood cell proliferation. From the 1950s, hydroxyurea began to be used as a myelosuppressive agent. In 1967, Dameshek proposed the concept of grouping PV, essential thrombocythemia, primary myelofibrosis, and chronic myeloid leukemia together as the "myeloproliferative disorders". This classification was the result of the recognition that these diseases share a common hematopoietic stem cell origin.

The most dramatic turning point in the history of PV research was the discovery of the JAK2 V617F mutation in 2005. Four independent research groups (Kralovics et al. in Nature; Levine et al. in Cancer Cell; Baxter et al. in Lancet; James et al. in Nature) simultaneously discovered, in about 95% of PV patients, a somatic gain-of-function mutation in the JAK2 (Janus kinase 2) gene in which valine is replaced by phenylalanine at amino acid 617. This discovery fundamentally changed the understanding of the pathogenesis of PV and related myeloproliferative neoplasms and laid the foundation for molecular diagnostics and the development of targeted therapies (JAK2 inhibitors). In the 2016 revision of the WHO classification, PV was reclassified as a "myeloproliferative neoplasm (MPN)".

In Korea, accurate epidemiological data on PV have been limited, but recent studies using health insurance data have confirmed a gradually increasing trend in prevalence. With the spread of JAK2 V617F testing, previously undiagnosed or misdiagnosed cases are gradually being diagnosed correctly.


2. Causes

The direct cause of polycythemia vera is a somatic gain-of-function mutation of the JAK2 gene. The JAK2 V617F (exon 14) mutation is found in about 97% of all PV patients, and JAK2 exon 12 mutations (F537-K539delinsL, H538QK539L, etc.) are found in the remaining about 3%. All of these mutations are located in the pseudokinase domain (JH2) of JAK2, abolishing the autoinhibitory function on JAK2 kinase activity and consequently constitutively activating erythropoietin (EPO) receptor signaling.

Interestingly, the JAK2 V617F mutation is also found in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), meaning that this mutation alone does not determine the specific phenotype of PV (predominantly erythroid proliferation). The variant allele frequency (VAF) is higher in PV, and a homozygous state (JAK2 V617F allele burden > 50%) is common, which partly explains the phenotypic difference between ET and PV. In addition, co-mutations in epigenetic regulator genes such as TET2, DNMT3A, ASXL1 are additionally acquired before or after the JAK2 V617F mutation and contribute to disease progression and complexity.

As evidence suggesting that PV is not explained by somatic mutations alone, familial clustering of PV has been reported in some studies, and 1–5% of PV patients have a family history. MPL mutations and EPO receptor mutations associated with hereditary thrombocytopenia and erythrocytosis have been reported as causes of rare hereditary PV-like disorders. It has also been proposed that environmental exposures (radiation, benzene) may contribute to the development of PV, but the evidence is limited.


3. Genetics

The key genetic abnormality of polycythemia vera is the V617F (c.1849G>T) point mutation of the JAK2 gene located on the short arm of chromosome 9 (9p24). This mutation replaces valine (V) with phenylalanine (F) at amino acid 617 of the JAK2 protein, disrupting the autoinhibitory function of the pseudokinase domain (JH2). As a result, JAK2 kinase activity is constitutively maintained, and the STAT5, STAT3, PI3K/AKT, and MAPK signaling pathways are persistently activated.

The variant allele frequency (VAF) of JAK2 V617F plays an important role in determining prognosis and phenotype. A VAF > 50% (homozygous state) is associated with increased thrombotic risk, splenomegaly, and increased risk of progression to myelofibrosis, and a higher VAF is generally observed in PV than in ET. JAK2 exon 12 mutations (about 3% of PV) cause a phenotype characterized by proliferation largely confined to the erythroid lineage and normal or reduced platelet counts.

Besides JAK2 mutations, concomitant genetic abnormalities observed in PV include TET2 mutations (about 15–20%, regulation of DNA demethylation), DNMT3A mutations (about 5–10%, regulation of DNA methylation), ASXL1 mutations (about 10%, chromatin remodeling), and SF3B1 and U2AF1 mutations (splicing factors). These co-mutations are sometimes acquired before JAK2 V617F (at the hematopoietic stem cell clonal expansion stage), are associated with disease progression (transformation to myelofibrosis, leukemic transformation), and are being studied for possible use as prognostic factors. In particular, ASXL1, SRSF2, IDH1/2, and EZH2 mutations are associated with an increased risk of progression from PV to myelofibrosis or acute leukemia.


4. General epidemiology

Polycythemia vera is a rare hematologic cancer whose annual incidence, although it varies somewhat by country, is reported to be about 1–2.8 per 100,000. In the United States, there are about 6,000–9,000 new cases annually, and the prevalence is about 57,000–65,000 people. In Europe, an incidence of about 1.9–2.3 per 100,000 is reported. Incidence in Asian countries tends to be lower than in the West; the exact annual incidence in Korea has not yet been systematically reported, but it is estimated at about 0.5–1.0/100,000 in analyses of health insurance data.

The median age at diagnosis is about 60–65 years, and onset before age 40 is rare at about 5–10%. Incidence is slightly higher in men than in women (male:female about 1.1–1.5:1), and some studies report that women tend to be diagnosed at a younger age. A higher incidence has been reported in Ashkenazi Jews, suggesting that genetic susceptibility is partly involved. PV, together with ET and PMF, which carry the same JAK2 V617F mutation, forms the myeloproliferative neoplasm (MPN) spectrum, and some patients diagnosed with PV at diagnosis may show clinical features overlapping with ET or PMF over the long term.


5. Pathophysiology

The key pathogenetic mechanism of PV is constitutive activation of the JAK-STAT signaling pathway by the JAK2 V617F mutation. In normal erythropoiesis, EPO binds to the EPO receptor (EpoR) on the surface of erythroid progenitor cells and phosphorylates JAK2, which in turn phosphorylates STAT5; STAT5 moves to the nucleus and activates transcription of target genes such as Bcl-xL (antiapoptotic gene) and Cyclin D1 (cell cycle progression). In PV, the JAK2 V617F mutation keeps JAK2 persistently activated even without EPO binding, causing EPO-independent proliferation of erythroid progenitor cells. This mechanism explains the low serum EPO levels and endogenous erythroid colonies (EEC, CFU-E that can be cultured without exogenous EPO) characteristic of PV.

Overexpression of Bcl-xL due to STAT5 activation leads to suppression of apoptosis and prolonged survival of erythroid progenitor cells. The accompanying increases in white blood cells and platelets occur because the effect of JAK2 V617F also appears in their respective progenitor cells. Thrombosis is the main complication of PV, with increased blood viscosity due to erythrocytosis, increased platelet activation, endothelial dysfunction, and increased leukocyte-platelet interaction contributing in combination. Neutrophils carrying JAK2 V617F have increased tissue factor expression, raising the coagulation tendency. During the long-term course, bone marrow fibrosis (post-PV MF transformation) is caused by oversecretion of profibrotic cytokines such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF) of megakaryocyte and monocyte origin.


6. Symptoms

The symptoms of PV are broadly divided into blood hyperviscosity due to increased red cells, thrombotic tendency, and systemic symptoms of the disease itself. The most characteristic symptom is aquagenic pruritus, in which severe itching of the skin occurs after contact with hot water (bathing, showering). This symptom is reported in about 40–70% of PV patients and is caused by excessive release of histamine from activated mast cells and basophils. Aquagenic pruritus seriously affects quality of life and is often difficult to treat.

Among microvascular symptoms, erythromelalgia (burning, pain, and redness of the fingertips and toes) is characteristic. It is caused mainly by platelet-mediated small vessel occlusion and is effectively controlled with low-dose aspirin. Headache, dizziness, tinnitus, visual disturbances, and decreased concentration due to excessive blood cell counts are common. Systemic symptoms may include fatigue, night sweats, weight loss, and bone pain. Thromboembolism occurs in about 30–40% of patients and may present as stroke, myocardial infarction, deep vein thrombosis, or Budd-Chiari syndrome. Left upper quadrant pain and early satiety due to splenomegaly are also common symptoms.


7. Signs

The most prominent sign on physical examination is flushing of the face and oral mucosa, and some patients have a plethoric appearance resembling chronic carbon monoxide poisoning. Splenomegaly is found in about 70% of PV patients, and in severe cases the lower pole of the spleen is palpable down to the level of the umbilicus. Splenomegaly reflects extramedullary hematopoiesis and enlarges further as the disease progresses. Hepatomegaly is observed in about 30–40%.

Conjunctival injection (vasodilation) and a red hue of the oral mucosa and tongue are found. Hypertension is often present, with hypertension measurable by sphygmomanometer present in about 30–40%. With erythromelalgia, redness and tenderness of the fingertips and toes are observed. Neurological and vascular sequelae such as hemiparesis, aphasia, and lower limb edema due to previous thromboembolism may be found on examination. Scratch marks due to pruritus are observed on the skin throughout the body. In some patients, joint swelling and redness of gouty arthritis (due to increased uric acid) are found.


8. Screening

In most cases, the diagnostic process for PV begins when an elevated hematocrit or hemoglobin is discovered incidentally on routine blood tests. PV should be suspected when there is aquagenic pruritus, unexplained thromboembolism, or hemoconcentration with splenomegaly. When routine health checkup blood tests in people aged 40 or older show Hb > 16.5 g/dL, Hct > 49% in men or Hb > 16.0 g/dL, Hct > 48% in women, JAK2 V617F testing is performed together with differentiation from secondary erythrocytosis.

When there is familial PV or MPN, JAK2 testing and complete blood counts of relatives are recommended. JAK2 V617F testing is currently the single most useful known screening test and is used to identify PV with a sensitivity of about 95% or more. Measurement of the serum EPO (erythropoietin) level helps differentiate secondary erythrocytosis, and in PV the EPO level is usually suppressed to below normal. In addition, MPN-related JAK2 testing is recommended in patients with Budd-Chiari syndrome of unknown cause, splanchnic vein thrombosis, or stroke at a young age.


9. Diagnosis

According to the 2022 WHO classification of hematolymphoid tumors, PV can be diagnosed when all 3 major criteria or the first 2 major criteria + 1 minor criterion are met.

The major criteria are ① hemoglobin > 16.5 g/dL (men) or > 16.0 g/dL (women), or hematocrit > 49% (men) or > 48% (women), or increased red cell mass; ② bone marrow biopsy showing trilineage proliferation (panmyelosis: erythroid, granulocytic, megakaryocytic), especially with pleomorphic mature megakaryocytes (marrow fibrosis grade 1 or less possible); ③ positive JAK2 V617F or JAK2 exon 12 mutation. The minor criterion is a serum EPO level suppressed below the reference range. In addition, an endogenous erythroid colony (EEC) formation assay may be used as an adjunct but is rarely performed in routine practice.

Bone marrow biopsy is important for confirming the diagnosis and assessing the fibrosis grade. Characteristic bone marrow findings in PV are panmyelosis (increases in erythroid, granulocytic, and megakaryocytic lineages), megakaryocytic pleomorphism (variable size and maturity), increased cellularity (hypercellularity), and absent or minimal reticulin fiber increase (MF-0–1). Distinguishing the PCV (polycythemia vera) vera phase from the spent phase (spent or post-PV myelofibrosis phase) is important for treatment decisions.


10. Treatment

The main goals of PV treatment are reducing the risk of thromboembolism, controlling symptoms, and delaying disease progression (myelofibrosis, acute leukemia). Phlebotomy and low-dose aspirin (100 mg/day) are the basic treatment for all PV patients. The phlebotomy goal is to maintain hematocrit < 45% (same for men and women), and in the CYTO-PV randomized trial, cardiovascular death and thromboembolism were significantly reduced in the group maintained at hematocrit < 45% compared with the group maintained at > 45% (HR 0.25). Aspirin is effective for controlling microvascular symptoms and preventing thrombosis and is recommended for all patients unless contraindicated.

In the high-risk group (age > 60 years or history of thromboembolism), cytoreductive therapy is added. As the first-line agent, hydroxyurea is the most widely used and reduces white cells, platelets, and red cells. With long-term use, there are concerns about skin ulcers, stomatitis, and secondary leukemia. Pegylated interferon alfa (ropeginterferon alfa-2b, PEG-IFN-α) has been shown to reduce JAK2 VAF and is a treatment with the potential for molecular remission, preferred especially in young patients. In Europe, ropeginterferon alfa-2b (Besremi) has been approved as a first-line treatment for PV. Ruxolitinib is effective in controlling blood counts, reducing spleen size, and relieving pruritus in patients resistant or intolerant to hydroxyurea and has received FDA and EMA approval. When night sweats and pruritus are severe, antihistamines and PUVA phototherapy are used as adjuncts.


11. Prognosis

PV is a chronic hematologic neoplasm that allows relatively long-term survival with appropriate treatment. In US SEER data, the 5-year relative survival rate is about 88.3%, and median survival is reported to be about 11.9 years. The main reasons survival is shorter than in the general population are thromboembolism (arterial and venous), bleeding, and late complications (post-PV myelofibrosis, secondary acute myeloid leukemia). Thromboembolism is the most common cause of death, accounting for about 40–50% of PV-related deaths.

During the long-term course, transformation to post-PV myelofibrosis (post-PV MF) occurs in about 10–20%, with a 10-year risk after onset of about 10–15%. Transformation to acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is about 2–3% (10-year cumulative) and may be partly associated with long-term hydroxyurea use. As prognostic factors, age (>60 years), elevated white cell count (WBC > 10×10⁹/L), JAK2 V617F VAF, and co-mutations (ASXL1, SRSF2, IDH1/2) are associated with a poor prognosis. The international PV prognostic scoring system (IPSET-thrombosis) is used to classify thrombotic risk as low, intermediate, or high.


12. Prevention

Primary prevention of PV itself is difficult because there is currently no way to prevent acquisition of the known causative factor (JAK2 somatic mutation). However, secondary prevention of complications (thromboembolism, bleeding) after a PV diagnosis is central to treatment. Regular phlebotomy to keep the hematocrit below 45% is the most important means of preventing thrombosis. The phlebotomy interval varies between individuals but is initially once or twice a week and thereafter maintained at intervals of several months. Regular use of low-dose aspirin is effective in preventing microvascular thrombosis and major thrombotic events.

Active control of cardiovascular risk factors is an important additional strategy to lower thrombotic risk. Smoking cessation greatly reduces thrombotic risk, and treatment of hypertension, diabetes, and hyperlipidemia and resolution of obesity are recommended. Prophylactic anticoagulation is considered for long-haul flights or high-risk surgery. Regular use of drug therapy (hydroxyurea, interferon, ruxolitinib) and monitoring of blood counts through regular blood tests are essential for preventing complications and timely adjustment of treatment. Lifestyle modifications such as lowering bath water temperature, using antihistamines, and PUVA phototherapy to relieve pruritus are also important for maintaining quality of life.


13. References

  1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2024 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2024;99(1):148-162. DOI: 10.1002/ajh.27002. PMID: 38109329.

  2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. DOI: 10.1056/NEJMoa051113. PMID: 15858187.

  3. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33. DOI: 10.1056/NEJMoa1208500. PMID: 23216699.

  4. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. DOI: 10.1056/NEJMoa1409303. PMID: 25629741.

  5. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072. DOI: 10.1182/blood-2008-03-143537. PMID: 18618958.

  6. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-1069. DOI: 10.1038/s41375-018-0077-1. PMID: 29515238.

  7. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881. DOI: 10.1038/leu.2013.163. PMID: 23739289.

  8. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-761. DOI: 10.1016/j.amjmed.2004.06.032. PMID: 15541328.

  9. Gisslinger H, Klade C, Giorgio A, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196-e208. DOI: 10.1016/S2352-3026(19)30236-4. PMID: 31980388.

  10. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228. DOI: 10.1182/blood.2022015850. PMID: 35767897.